Journal of Diabetes Research最新文献

{"title":"Increased Urinary Extracellular Vesicles and Reduced Expression of NEDD4L in Patients With Type 2 Diabetes and Diabetic Nephropathy.","authors":"Nikhil Thyagarajan, Richard Le Leu, Sharad Kumar, Shilpanjali Jesudason, Jantina A Manning","doi":"10.1155/jdr/3850490","DOIUrl":"https://doi.org/10.1155/jdr/3850490","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic nephropathy (DN) is a leading cause of chronic kidney disease. Current diagnosis requires the persistent presence of albuminuria and/or reduction in estimated glomerular filtration rate, often detected only at late stages of disease. In recent years, extracellular vesicles (EVs), lipid bilayer membrane-enclosed particles that shed from cells, have gained momentum as a potential source of biomarkers for DN, reflecting pathological changes in this condition. Our previous work has demonstrated robust expression of the NEDD4L ubiquitin ligase in urinary EVs, with the loss of this protein in mice resulting in kidney disease. Reduced NEDD4L expression has been reported in the kidneys of patients with DN. Hence, in this study we analysed NEDD4L expression in kidney biopsies from patients with Type 2 diabetes mellitus (T2DM) and DN, as well as the release of urinary EVs from patients with DN and control subjects without diabetes. We assessed whether the level of NEDD4L in these vesicles reflects NEDD4L expression in kidney biopsy samples.</p><p><strong>Methods: </strong>Kidney biopsies (slides of control healthy kidney tissue taken adjacent to a suspected tumour site from five patients who had performed biopsy for suspicion of oncological pathology, and slides of kidney tissue from five patients with T2DM and DN) were utilised. Urine samples (from 21 control participants without diabetes, and from 21 patients with T2DM and DN) were collected. EVs were isolated and characterised from urine samples. NEDD4L protein expression levels were assessed in kidney biopsies and urinary EV samples.</p><p><strong>Results: </strong>Urine samples from patients with DN exhibited a heterogeneous population of EVs, with increased EV numbers and protein concentrations compared with controls without diabetes. Within EVs, NEDD4L protein expression was significantly reduced in patients with DN as compared with controls without diabetes.</p><p><strong>Conclusion: </strong>We reported a higher concentration of a heterogeneous population of urinary EVs in patients with T2DM and DN, with decreased NEDD4L protein levels that reflect the findings observed in the kidney biopsy samples of such patients. These findings support the potential use of urinary EVs as biomarkers of T2DM-related DN and suggest that lower NEDD4L levels within these vesicles may be an indicator of the extent of DN-associated tubular injury.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"3850490"},"PeriodicalIF":3.4,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12968427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147433186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Evidence Reveals Causal Effect of Circulating Proteome on Random Glucose: A Mendelian Randomization Study.","authors":"Ziyuan Shen, Xing Xing, Xiaoyue Zhang, Jianan Zhu, Yining Wang, Guoqi Cai","doi":"10.1155/jdr/6662650","DOIUrl":"10.1155/jdr/6662650","url":null,"abstract":"<p><strong>Background: </strong>Random glucose (RG) testing provides greater flexibility and convenience, enabling real-time evaluation of blood glucose levels without the need to consider recent dietary intake. This study was aimed at identifying drug targets using the evidence from circulating proteins associated with RG from genome-wide association studies (GWASs).</p><p><strong>Methods: </strong>Using two-sample Mendelian randomization (MR) with circulating protein data from nine GWAS, we revealed potential causal relationships between these proteins and RG. A framework of sensitivity analyses was performed to assess the robustness and credibility of the evidence.</p><p><strong>Results: </strong>In the <i>cis</i>-protein quantitative trait loci (pQTLs) and the combined <i>cis</i>/<i>trans</i>-pQTLs analyses, 12 and 31 proteins demonstrated causal effects on RG, respectively. Enrichment analysis revealed that proteins prioritized by <i>cis</i>-MR were enriched in the carbohydrate catabolic process, collagen-containing extracellular matrix, and peptidase regulator activity. For all MR-prioritized proteins, pathways were enriched in those related to the maintenance of location, secretory granule lumen, sulfuric ester hydrolase activity, and regulation of lipolysis in adipocytes. Notably, approximately half of these proteins (including PCSK1, PPY, and VWF) were recognized as druggable or existing drug targets.</p><p><strong>Conclusions: </strong>This study identified proteins causally linked to RG, emphasizing their potential role in the development of therapeutic interventions for metabolic disorders, particularly those involving glucose regulation.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"6662650"},"PeriodicalIF":3.4,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shenqi Dihuang Decoction Attenuates ALOX5-Mediated Ferroptosis in Diabetic Nephropathy via AMPK/mTOR and TGF-<i>β</i>/Smads Pathways.","authors":"Li Zhao, Danna Zheng, Wenjuan Gu, Yanna Liu, Jinlong Lyu","doi":"10.1155/jdr/2872977","DOIUrl":"10.1155/jdr/2872977","url":null,"abstract":"<p><p>To explore the underlying mechanisms about that Shenqi Dihuang decoction (SDD) attenuated diabetic nephropathy (DN), mice were fed on high-sugar and high-fat diet and treated with streptozotocin (STZ) to induce DN model, as well as HK-2 cells treated with D-glucose to establish a DN cell model. High-performance liquid chromatography (HPLC) analysis was carried out to excavate the chemical compositions existed in SDD. The network pharmacological analysis was performed to screen the key genes involved in SDD treating DN. Subsequently, the effects of SDD on ALOX5, ferroptosis- and AMPK/mTOR pathway-associated indices were examined. Finally, whether SDD attenuated ALOX5-mediated ferroptosis in DN via AMPK/mTOR and TGF-<i>β</i>/Smads pathways were validated using gain-of-function experiment. SDD exerted a therapeutic effect on DN mice by improving kidney function, kidney fibrosis and reducing inflammation. HPLC analysis detected two chemical compositions in SDD, containing syringic acid and gallic acid ethyl ester. Network pharmacological analysis found that SDD might inhibit DN by targeting ALOX5. In addition, SDD treatment decreased ROS, MDA, iron, ALOX5, p-mTOR/mTOR, TGF-<i>β</i>1, p-Smad2/3/Smad2/3 levels in DN, whereas elevated the levels of SLC7A11, GPX4 and p-AMPK/AMPK. These changes were reversed upon upregulation of ALOX5 gene expression. In conclusion, SDD inhibits ALOX5-mediated ferroptosis in DN via AMPK/mTOR and TGF-<i>β</i>/Smads pathways.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"2872977"},"PeriodicalIF":3.4,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12957774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship Between Serum Levels of Unsaturated Fatty Acids and Type 2 Diabetes Mellitus: A Cross-Sectional Analysis of NHANES 2003-2004 and 2011-2012.","authors":"Shan Liu, Ying Liu, Lipeng Liu, Fengxia Lv, Huijuan Wang, Xiuyun Zhang, Shuxia Yue, Liwen Zhang, Jin Zhou","doi":"10.1155/jdr/1153035","DOIUrl":"10.1155/jdr/1153035","url":null,"abstract":"<p><strong>Objective: </strong>The role of serum fatty acids in Type 2 diabetes mellitus (T2DM) remains unclear. We aimed to assess and compare the associations of multiple serum unsaturated fatty acids with the prevalence of T2DM to elucidate their heterogeneous relationship profiles.</p><p><strong>Methods: </strong>This study used the data from the National Health and Nutrition Examination Surveys (2003-2004 and 2011-2012). Weighted proportional and multivariate logistic regression analyses were conducted to evaluate the associations of serum polyunsaturated fatty acids (PUFAs) and monounsaturated fatty acids (MUFAs) with T2DM status and to adjust for potential confounders.</p><p><strong>Results: </strong>The study included 3760 individuals. Results of the multivariate logistic regression analyses showed that among the serum PUFAs, docosapentaenoic acid (DPAn3) (22:5 n3) was associated with lower odds of T2DM (odds ratio [OR]: 0.595, 95% CI: 0.375-0.942, <i>P</i> _trend = 0.028). Arachidonic acid (AA) (20:4(20: 4 n6) and linoleic acid (LA) (18:2 n6) were negatively associated with T2DM prevalence (OR in quintile 5: AA [20:4 n6] = 0.396, 95% CI: 0.232-0.674, <i>P</i> _trend = 0.002; LA (18:2 n6) = 0.277, 95% CI: 0.163-0.472, <i>P</i> _trend < 0.001). Moreover, among the MUFAs, oleic acid (OA) (18:1 n9) and eicosenoic acid (EA) (20:1 n9) were associated with increased odds of T2DM, whereas nervonic acid (NRA) (24:1 n9) was associated with decreased odds of T2DM. Furthermore, nonlinear analyses showed that the n-6 PUFAs dihomo-<i>γ</i>-linolenic acid (DGLA) (20:3 n6) and AA (20:4 n6), as well as the n-9 MUFA EA (20:1 n9), had nonlinear associations with T2DM.</p><p><strong>Conclusions: </strong>Our findings suggest that several serum n-3 and n-6 PUFAs are inversely associated with T2DM prevalence, whereas some n-9 MUFAs are positively associated with T2DM prevalence. These findings provide comprehensive descriptive data on the serum fatty acid profile in relation to T2DM and underscore the heterogeneity of associations across individual fatty acid species.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"1153035"},"PeriodicalIF":3.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12950622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Parental Overreactivity and Laxness in Diabetes Outcomes Among Children and Adolescents With Type 1 Diabetes.","authors":"Alessa Thomas, Su-Jong Kim-Dorner, Olga Kordonouri, Bettina Heidtmann, Thomas M Kapellen, Simone von Sengbusch, Roland Schweizer, Karin Lange, Heike Saßmann","doi":"10.1155/jdr/2480622","DOIUrl":"10.1155/jdr/2480622","url":null,"abstract":"<p><strong>Introduction: </strong>Parental disciplinary behaviors, such as <i>overreactivity</i> and <i>laxness</i>, can negatively affect children's behavior and well-being. We examined ove<i>rreactivity</i> and <i>laxness</i> in relation to parental emotional well-being and the behavioral, glycemic, and psychological outcomes of children and adolescents with T1D.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted at five pediatric diabetes centers. Parents provided demographic and clinical information and completed questionnaires assessing parenting behavior, diabetes-specific distress, and depressive symptoms. Children reported their frequency of glucose checking and diabetes distress. Correlation and regression analyses were used. Child age was stratified into three groups (7-10, 11-14, and 15-18 years) for subgroup analyses.</p><p><strong>Results: </strong>A total of 677 parents (mean age = 43.9 [±6.3] years, 77.1% mothers) and 654 children (mean age = 12.4 [±2.8] years, 44.7<i>%</i>female, diabetes duration = 5.4 [±3.8] years) participated. With increasing child age, parents reported less <i>overreactivity</i> (<i>r</i> = -0.114, <i>p</i> = 0.003) and more <i>laxness</i> (<i>r</i> = 0.104, <i>p</i> = 0.007). Higher <i>overreactivity</i> and <i>laxness</i> were associated with greater parental diabetes distress (<i>r</i> = 0.335, <i>p</i> < 0.001; <i>r</i> = 0.119, <i>p</i> < 0.01) and more depressive symptoms (<i>r</i> = 0.314, <i>p</i> < 0.001; <i>r</i> = 0.100, <i>p</i> < 0.01). After adjusting for demographic and clinical variables, both disciplinary behaviors were significant factors in child diabetes distress, and <i>laxness</i> predicted less frequent glucose checking. Age-stratified analyses showed that <i>overreactivity</i> was linked to greater diabetes distress in children aged 7-10 years. <i>Laxness</i> was associated with fewer glucose checks in the 7-10 and 15-18-year groups and with higher HbA1c and diabetes distress in adolescents aged 15-18 years.</p><p><strong>Conclusions: </strong>Parents appear to use more <i>overreactivity</i> with younger children and more <i>laxness</i> as children age. Both behaviors are associated with poorer diabetes-related outcomes. Supporting effective parenting practices may improve psychological well-being and self-management of youth with T1D.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"2480622"},"PeriodicalIF":3.4,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12948729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Provider Prescribing Practices for GLP-1RAs and SGLT-2is in Patients With Type 2 Diabetes to Address Pharmacoinequity.","authors":"Parnnate Wongsirisakul, Vincent L Chen, Ponni V Perumalswami","doi":"10.1155/jdr/7439681","DOIUrl":"10.1155/jdr/7439681","url":null,"abstract":"<p><strong>Background and aims: </strong>Evidence-based treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with Type 2 diabetes (T2DM) focuses on glycemic control and lifestyle modification to achieve weight loss, which slows the progression of liver disease and reduces the risk of liver-related complications. We aimed to qualitatively explore provider-level determinants in glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 inhibitors (SGLT-2is) prescription.</p><p><strong>Methods: </strong>We identified a cohort of 189 outpatient adult primary care providers who cared for at least 50 annual T2DM patients in a tertiary academic health system in the United States in 2021. GLP-1RA and SGLT-2i prescribing rates were calculated with a median rate of 0.494 (IQR 0.393-0.594). Guided by the Consolidate Framework for Implementation Research, we conducted 1:1 interviews with high-prescribing and low-prescribing providers. All providers interviewed were either MDs or DOs.</p><p><strong>Results: </strong>Nine providers from the high-prescribing quartile (prescribing rate 59.5%-78.6%) and eight from the low-prescribing quartile (prescribing rate 4.8%-39.3%) were interviewed. High-prescribing providers reported more patient-facing hours and exposure to GLP-1RAs and SGLT-2is in residency. All providers cited task-sharing, patient-provider relationship longevity, and medication effectiveness as facilitators of GLP-1RA and SGLT-2i prescription. Barriers to prescribing included medication costs, prior authorization processes, and prescription inertia. Using the Expert Recommendations for Implementing Change, we mapped barriers and facilitators to implementation strategies.</p><p><strong>Conclusions: </strong>This interview series identified key barriers and facilitators of GLP-1RA and SGTL-2i prescription. Implementation strategies may help improve prescribing highly effective, newer treatments in patients with T2DM, including those with metabolic comorbidities.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"7439681"},"PeriodicalIF":3.4,"publicationDate":"2026-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12943470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147326295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Metabolic Assessment: Maximal Fat Metabolism, Lactate Dynamics, and Cardiorespiratory Determinants at Different Pedaling Frequencies.","authors":"Ahmad Alkhatib","doi":"10.1155/jdr/2259315","DOIUrl":"10.1155/jdr/2259315","url":null,"abstract":"<p><strong>Aims/objectives: </strong>Accurate metabolic exercise testing is essential for assessing cardiometabolic health in both athletes and clinical populations with prediabetes and diabetes. This study investigated whether and how fat, carbohydrates and lactate diagnostics are influenced by ergometry testing pedaling frequency.</p><p><strong>Methods: </strong>This randomized cross-over repeated-measures trial, examined human participants for cardiorespiratory oxygen uptake ( <math><mover><mi>V</mi> <mo>.</mo></mover> <msub><mrow><mi>O</mi></mrow> <mrow><mn>2</mn></mrow> </msub> </math> ) and carbon dioxide production ( <math><mover><mi>V</mi> <mo>.</mo></mover> <mi>C</mi> <msub><mrow><mi>O</mi></mrow> <mrow><mn>2</mn></mrow> </msub> </math> ), and blood lactate concentration (BLC), using two separate incremental load ergometry exercise tests until exhaustion, at higher versus lower cycling pedaling frequencies of 100 and 50 revolution per minute (RPM). Metabolic diagnostics of fatty acid oxidation (FAO), carbohydrates oxidation (CHO), maximal FAO (MFO) and associated MFO intensity (Fatmax) were estimated by stoichiometric equations and compared at 100 versus 50 RPM.</p><p><strong>Results: </strong>Higher <math><mover><mi>V</mi> <mo>.</mo></mover> <msub><mrow><mi>O</mi></mrow> <mrow><mn>2</mn></mrow> </msub> </math> , <math> <mover><mrow><mi>V</mi> <mi>C</mi></mrow> <mo>.</mo></mover> <msub><mrow><mi>O</mi></mrow> <mrow><mn>2</mn></mrow> </msub> </math> , BLC and CHO and lower FAO were found for all submaximal intensities at 100 RPM than at 50 RPM (all <i>p</i> < 0.01). Fatmax power output was significantly lower (83.7 ± 20.3 vs. 99.8 ± 25.8 <i>W</i>, <i>p</i> < 0.05, effect size <i>d</i> = 0.70) at 100 than at 50 RPM. However, pedaling frequency-dependent effects reflected nonsignificant changes in MFO (0.58 ± 0.16 vs. 0.52 ± 0.15 g.min^-1, <i>p</i> = 0.12, <i>d</i> = 0.39), and also in the corresponding BLC at MFO (1.70 ± 0.45 vs. 1.30 ± 0.39  mmol.L^-1, <i>p</i> = 0.06, <i>d</i> = 0.9).</p><p><strong>Conclusions: </strong>Metabolic assessments should prioritize absolute MFO and BLC dynamical changes over Fatmax intensities, when interpreting fat-oxidation capacity, particularly under varying pedaling frequencies. By jointly characterizing blood-based and respiratory-based diagnostics under different exercise assessment conditions, this study helps improve the reliability of diagnosing the metabolic status in both healthy individuals and patients with metabolic disease.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"2259315"},"PeriodicalIF":3.4,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12933878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Role of Physical Exercise and Exercise-Induced FNDC5/Irisin in Combating Diabetes-Related Cognitive Impairment and Autonomic and Peripheral Neuropathies: A Comprehensive Review.","authors":"Sepideh Poshtdar, Hosein Ataei-Goujani, Amirali Ahrabi","doi":"10.1155/jdr/5552311","DOIUrl":"https://doi.org/10.1155/jdr/5552311","url":null,"abstract":"<p><p>The rising prevalence of diabetes has been closely linked to increased mortality and morbidity, particularly as its complications become more widespread. Among the most challenging of these complications are cognitive impairments and diabetic neuropathies, which are neurodegenerative conditions that significantly diminish the quality of life in the diabetic population. Beyond its well-established benefits for improving glycemic control and preventing cardiovascular complications, physical exercise has also been shown to mitigate central and peripheral neurodegenerative complications of diabetes, including cognitive decline, peripheral neuropathies, and autonomic neuropathies. Emerging research suggests that fibronectin type III domain-containing protein 5 (FNDC5), later converted into irisin, an exercise-induced myokine, plays a key role in mediating these protective effects. This narrative review thoroughly examines the protective impact of various forms of physical exercise-including aerobic, resistance, and multimodal training-on diabetic neuropathies and cognitive decline, while also exploring the involvement of FNDC5/irisin in these beneficial outcomes across experimental animal studies, cross-sectional analyses, and controlled trials.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"5552311"},"PeriodicalIF":3.4,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Use of Hybrid Closed-Loop Systems in People With Type 1 Diabetes and Their Partners: A Qualitative Evaluation From the NHS England Pilot.","authors":"Jennifer Hagan, Tomás P Griffin, Radhika Chauhan, Pratik Choudhary, Thomas S J Crabtree, Dawn Ackroyd, Emma G Wilmot, Parth Narendran, Zosanglura Bawlchhim, Jackie Elliott, Michelle Hadjiconstantinou","doi":"10.1155/jdr/1997861","DOIUrl":"https://doi.org/10.1155/jdr/1997861","url":null,"abstract":"<p><strong>Aims: </strong>The NHS England hybrid closed-loop (HCL) insulin pump pilot offered people living with Type 1 diabetes (PWT1Ds) access to HCL therapy. Outcomes demonstrated the glycaemic benefits of HCL. Our study explored the views, experiences and impact of HCL on users and their partners' daily life.</p><p><strong>Methods: </strong>A total of 14 PWT1Ds and 12 partners of PWT1Ds who participated in the NHS HCL pilot took part in semistructured interviews via telephone/video call. Topics explored included the effect of the HCL system on glucose levels, time spent managing diabetes, daily life and challenges with the systems. Interviews were audio-recorded and transcribed. Data was analysed using inductive thematic analysis and then mapped onto an adapted Optimal Health Wheel (OHW) framework encompassing four relevant domains: (i) emotional, (ii) intellectual, (iii) social and (iv) physical.</p><p><strong>Results: </strong>Ten subthemes relating to the impact or experience of using HCL emerged-knowledge and previous experience, time/trial and error, building trust, impact on mental wellbeing, impact on physical health, impact on diabetes management, impact on lifestyle, impact on work, impact on relationships and need for support. PWT1Ds and partners reported multifaceted physiological and psychosocial benefits of using HCL systems. While technical difficulties and initial learning hurdles were acknowledged as barriers to HCL use, facilitators such as previous experience and trial and error helped overcome these issues.</p><p><strong>Conclusions: </strong>PWT1Ds and their partners endorsed the use of HCL systems, despite challenges, due to the impactful benefits to their lives. To ensure future successful implementation of HCL, users should be offered appropriate training and access to support to help build trust. These findings underscore the potential of HCL systems in T1D treatment.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"1997861"},"PeriodicalIF":3.4,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12909262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146220023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of Free Triiodothyronine With Sarcopenia Among Patients With Type 2 Diabetes: Cross-Sectional and Sex-Stratified Analyses.","authors":"Jing Zhao, Mei-Tong Zhang, Dan Yu, Zi-Yue Shao, Da-Shuang Chen, Jian Zhu","doi":"10.1155/jdr/3134701","DOIUrl":"10.1155/jdr/3134701","url":null,"abstract":"<p><strong>Objective: </strong>Sarcopenia is prevalent in Type 2 diabetes mellitus (T2DM). Whether thyroid-related hormones within the euthyroid range can help identify sarcopenia risk remains unclear. This study was aimed at evaluating the association of euthyroid-range thyroid markers with sarcopenia and their utility in risk stratification among adults with T2DM.</p><p><strong>Methods: </strong>We analyzed 1823 adults with T2DM (2019-2023). Sarcopenia was defined per Asian Working Group for Sarcopenia 2019 criteria. Muscle mass was assessed via multifrequency bioelectrical impedance analysis, handgrip strength via dynamometer, and gait speed via 6-m walk test. Multivariate linear and logistic models were adjusted for demographics, diabetes duration, body mass index, nephropathy, glycated hemoglobin, and antidiabetic medications. Discriminatory ability was evaluated using receiver operating characteristic curves, change in the area under the receiver operating characteristic curve (<i>Δ</i>AUROC), and net reclassification indices (net reclassification improvement [NRI]; bootstrapped).</p><p><strong>Results: </strong>Higher free triiodothyronine (FT3) levels correlated with greater muscle mass, handgrip strength, and gait speed. Among thyroid markers, FT3 showed the strongest discrimination for sarcopenia (AUROC = 0.633). The optimal cutoff was 3.62 pmol/L (sensitivity, 85.6% and specificity, 35.7%), although overall performance was modest. Low FT3 independently predicted sarcopenia (odds ratio [OR], 2.26; <i>p</i> = 0.002). The association remained significant in females (OR, 3.29) but not in males (OR, 1.83); no sex interaction was detected. Adding FT3 modestly improved the adjusted model (<i>Δ</i>AUROC, 0.007; NRI significant at 25th percentile risk).</p><p><strong>Conclusion: </strong>FT3 provides modest but superior discrimination than thyroxine or thyroid-stimulating hormone and may support early sarcopenia risk detection in T2DM, particularly at low levels, with a possible sex-specific pattern but no significant interaction.</p>","PeriodicalId":15576,"journal":{"name":"Journal of Diabetes Research","volume":"2026 ","pages":"3134701"},"PeriodicalIF":3.4,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146157269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}